Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

Go back to Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Delayed: 1.03 --0 (-0%)
Previous Close $1.03    52 Week High $3.50 
Open $1.02    52 Week Low $0.86 
Day High $1.04    P/E N/A 
Day Low $1.02    EPS $-7.61 
Volume 19,385